drugset / Trial / NCT03566511
Use of Functional MRI to Assess Functional Hypothalamic Activation in Response to Diazoxide
Phase 2
Terminated
37 enrolled
Meredith Hawkins
American Diabetes Association · collabNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collab
RandomizedCrossoverSingle-blindBasic science
Summary
The goal of this study is to determine whether metabolic control centers in the brain can be activated in patients with type 2 diabetes (T2D) as compared to non-diabetic individuals. This is important since people with diabetes have inappropriately high production of glucose, which could be at least in part due to impaired activation of important brain centers.
Timeline
- Start
- 2018-06-12
- Primary completion
- 2020-08-01
- Completion
- 2020-08-01
Outcome
Outcome not reported
Stopped (Business): “Grant funding ended. NIDDK grant renewed without an MR aim. No plans to do future studies.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Diazoxide | Unknown | 4 mg/kg | Oral |
| Subject | Diazoxide | Unknown | 7 mg/kg | Oral |